Antigen-specific, CD8+, cytolytic T lymphocytes (CTLs) could potentially provide resistance to several infectious and malignant diseases. However, the cellular requirements for the generation of specific CTLs in human lymphocyte cultures are not well defined, and repetitive stimulation with antigen is often required. We find that strong CD8+ CTL responses to influenza virus can be generated from freshly isolated blood T cells, as long as dendritic cells are used as antigen presenting cells (APCs). Small numbers of dendritic cells (APC:T cell ratio of 1:50-1:100) induce these CTL responses from most donors in 7 d of culture, but monocytes are weak or inactive. Whereas both dendritic cells and monocytes are infected with influenza virus, the former serve as effective APCs for the induction of CD8+ T cells while the latter act as targets for the CTLs that are induced. The strong CD8+ response to influenza virus-infected dendritic cells is accompanied by extensive proliferation of the CD8+ T cells, but the response can develop in the apparent absence of CD4+ helpers or exogenous lymphokines. CD4+ influenza virus-specific CTLs can also be induced by dendritic cells, but the cultures initially must be depleted of CD8+ cells. These findings should make it possible to use dendritic cells to generate human, antigen-specific, CD8+ CTLs to other targets. The results illustrate the principle that efficient T cell-mediated responses develop in two stages: an afferent limb in which dendritic cells are specialized APCs and an efferent limb in which the primed T cells carry out an immune response to many types of presenting cells. (J. Clin. Invest. 1994. 94:797-807.)
Introduction
The potential role of CD8+, cytolytic T lymphocytes' (CTLs) in resistance to infectious and malignant diseases has been reem- 1 . Abbreviations used in this paper: APC, antigen presenting cells; CTL, cytolytic T lymphocytes; ER+, T cell enriched; ER-, T cell depleted; HA, hemagglutinin; HRP, horseradish peroxidase; LCMV, lymphocytic choriomeningitis virus; MLR, mixed leukocyte reaction; NK, natural killer cells; NP, nucleoprotein; PE, phycoerythrin.
phasized by recent developments. Antigen-specific CTLs are recognized as a possible defense mechanism in infection with HIV-1 (1) (2) (3) , cytomegalovirus (4) , and in malaria (5) . Antigens that are recognized by melanoma-specific CTLs have also been identified by Van der Bruggen et al. (6) and Brichard et al. (7) . These studies document the specificity of CTLs that recognize clinically important targets. Less is understood about the initial generation of these CTLs, however.
As in most T cell responses, the precursors for active CTLs are quiescent lymphocytes that must be induced to expand clonally and develop effector functions. For CTL activation to occur, not only must antigens be presented as peptide fragments on MHC products, but the antigen-MHC complexes must also be introduced on cells with the requisite accessory functions that lead to T cell growth and cytolytic activity. There is evidence, primarily from the studies of killer cells to transplantation antigens, that an effective way to induce human CTLs is to present antigens on dendritic cells (8) . Dendritic cells are specialized accessory cells for the initiation of many T cell-dependent immune responses (for review see reference 9).
Here we have used dendritic cells to stimulate virus-specific CTLs from human blood. The model we chose to study was influenza. Improved mechanisms for prophylaxis and therapy are needed in influenza, because control of the respiratory infection is not readily achieved through current approaches to vaccination. For example, presently available vaccines are not designed to induce killer cells but instead boost antibody responses to viral antigens that undergo antigenic drift and shift (10) . It is known that dendritic cells are a component of the alveolar septae and airway epithelium of the lung (11, 12) and that the appearance of influenza virus-specific CTLs is associated with a more rapid clearance of virus from nasal washings (13) . Influenza virus is also the agent used to dissect the different pathways for antigen presentation and analyze the specificity of CTLs. Townsend and associates (14, 15) realized that viral proteins were processed in the cytoplasm and presented as peptides in association with class I MHC products of the infected cell. Morrison et al. (16) used influenza virus to distinguish the two pathways for antigen presentation to CTLs. One emanates from acidic endocytic vesicles and leads to presentation on MHC class II to CD4+ CTLs; the other emanates from a nonacidic biosynthetic compartment for presentation on MHC class I to CD8+ CTLs. The CTLs that have been the subject of work in humans are usually generated from unseparated blood mononuclear cells and/or repeated stimulation of responding lymphocytes with exogenous IL-2 and viral antigens (4, 5, 13, 14, 17- 22). For example, Carreno et al. (17) used repeatedly stimulated human blood cells in their elegant mapping studies of influenza peptides that are presented to CTLs. In this study, we identify an effective accessory cell system to generate human influenzaspecific killer cells.
We show that influenza A virus establishes a nontoxic infec-tion of human dendritic cells and that these infected dendritic cells induce the development of strong virus-specific CTLs within 7 d. Three features of the response will be stressed: both strong CD8+ T cell proliferation as well as CTL activity are evident, the killer cells once generated recognize and kill infected MHC class I-matched monocytes, and no exogenous cytokines or CD4+ helpers are required.
Methods
Culture medium RPMI 1640 (Gibco Laboratories, Grand Island, NY) supplemented with 100 yg/ml gentamicin, 5% human serum, and 10 mM Hepes buffer.
Blood mononuclear cells
In most experiments, buffy coats served as sources of PBMCs and were obtained from the New York Blood Center (New York, NY). Blood donors were also healthy volunteers who were HLA typed and selected for MHC class I mismatch. PBMCs were separated into T cellenriched (ER+) and T cell-depleted fractions (ER-) as previously described (23) . T cells. ER+ cells were first depleted of monocytes by panning on dishes coated with human gamma globulin (24). MHC class 11+ and natural killer (NK) cells (CD16+ and CD1 lb+) were depleted by coating with mAbs 9.3C9 (ATCC;HB 180), and 3G8 (gift of Dr. Jay Unkeless) and OKMI (ATCC;CRL 8026), respectively, followed by panning on petri dishes coated with goat anti-mouse IgG (8 (26) . Virus stocks were replenished from seed virus by Spafas Inc. (Storrs, CT) and stored in liquid nitrogen (virus stock: 20,000 HAU/ml). Virus titers were determined using a hemagglutination assay, as previously described (26) .
Infection of cells
APCs and target cells were washed out of medium containing serum and resuspended in RPMI at 0.5-1 x 107 cells/ml. Virus was added at a final concentration of 1,000 HAU PR8/ml and incubated for 60 min at 37°C. This dose is saturating for the induction of influenza-specific CTLs. To determine whether influenza infection proceeded through an acidic compartment in APCs, the cells were incubated in 10 mM NH4Cl for 30 min before adding virus and throughout the subsequent infection.
In some cases, the NH4Cl was added throughout the culture period, which was generally 24 h.
Induction of influenza-specific CTL 1 X 106 purified T cells were cultured in 24-well plates (Costar, Cambridge, MA) with graded doses of influenza virus-infected or uninfected APCs, in a total volume of 1.1 ml. After 7 d of culture, the cells were harvested and distributed in varying numbers to 96-well microtiter plates [100 Al per well]. CTL activity was measured using a 5"Cr-release assay with infected or uninfected syngeneic monocytes as targets. 1 X 104 targets in a volume of 50 jld were added to each well to generate E:T ratios ranging from 1:1 to 100:1.
SJCr release assay
Monocytes were obtained from ER-cells by adhering them onto plastic dishes for 60-90 min and dislodged by pipetting. 1 x 107 monocytes were cultured in 10 ml volumes in 60-ml Teflon beakers (Savillex Corp., Minnetonka, MN) until use as targets in the CTL assay (27) . For 5"Cr labeling and infection, cells were collected on ice, washed free of serum, and brought up to 1 x 107/ml in RPMI. 400 yCi Na51CrO4 (1 mCi/ml sterile stock; New England Nuclear, Boston, MA) was added per 1 x 10' monocytes. They were simultaneously infected with 1,000 HAU PR8/ml for 1 h at 370C. The targets were washed four times and resuspended at 2 x 105/ml, after which 50 sl was aliquoted to each well containing effector T cells. Spontaneous and total release samples were prepared by adding the targets to wells containing RPMI alone or a final concentration of 0.33% SDS, respectively. The plates were centrifuged for 2 min at 15 g and incubated for 5 h at 370C. At the termination of the assay, the supernatant was collected with absorption cartridges using a harvesting press (Skatron Instruments Inc., Sterling, VA) and counted in a gamma counter. Percent specific 5 
Results
Influenza virus uptake and infection in human dendritic cells. There is considerable evidence, primarily in mouse cell cultures, that dendritic cells effectively present viral antigens to T cells (26, (28) (29) (30) . Murine dendritic cells can be infected by influenza virus and elicit potent CTL responses (26, 29) . The responses are dependent upon the synthesis of endogenous viral proteins (26) . We wished to determine the extent to which human dendritic cells could be infected with influenza virus. Dendritic cells were isolated from buffy coat preparations as previously described and pulsed with live influenza virus for 1 h in serumfree medium. After multiple washes, immunohistochemistry was used to detect two viral proteins, NP and HA, within the cell, from 1 to 16 h after infection ( Fig. 1 ). In addition, dendritic cells were compared with macrophages isolated from the same donor.
Dendritic cells failed to stain with isotype-matched antibody OKT8 ( Fig. 1 A) but stained intensely with mAb to MHC class II ( Fig. 1 B) . At 16 h after infection, NP staining was primarily localized to the nucleus of dendritic cells, although there was clearly a cytoplasmic distribution in addition ( Fig. 1 C) . A diffuse distribution of HA, consistent with endogenous viral protein synthesis, was evident ( Fig. 1, D and E). Greater than 90% of the dendritic cells were infected by these criteria, with a viability of > 90%. The NP and HA patterns of staining at 16 h after infection indicate extensive synthesis of viral proteins in the dendritic cells. Uninfected dendritic cells did not stain with any mAbs for viral-specific proteins (data not shown).
After just 1 h of infection, dendritic cells expressed HA primarily in a granular pattern, suggesting that the virus is first contained within endocytic vacuoles ( Fig. 1 F) . Evidence of viral protein synthesis was also apparent in that there was diffuse cytoplasmic staining of a few cells at this early time point ( Fig. 1 F, 
black arrows). Pretreatment of dendritic cells with
NH4Cl before, during, and after a virus pulse blocked infection, i.e., few cells (< 2%) stained with either anti-HA or anti-NP mAbs (data not shown). These findings confirm that influenza requires an acidic compartment to deliver its genome to the cytoplasm and engage in viral-specific protein synthesis. Macrophages were also highly susceptible to infection with influenza. The degree of infection was generally > 70% ( Fig. 1 , G and H). After overnight incubation following infection, many cells died and appeared to be phagocytosed by viable macrophages ( Fig. 1 G, black arrow) . In contrast, dendritic cells showed no change in viability for up to 2 d after infection.
Lymphocytes also were examined by immunolabeling for their ability to be infected by influenza virus, but none appeared to be as infected as dendritic cells. B cells and T cells were not susceptible to infection as assessed by staining with anti-HA and NP mAbs. T cell blasts generated with superantigens had a low level of infection ( 10-30% of the-total T cell preparation), whereas EBV-transformed cells had weak staining in 10-30% of the cells. (Fig. 2) . Influenza-specific responses were detectable even when one dendritic cell was used per 300 T cells. At these stimulator/ responder ratios, influenza virus-pulsed macrophages and B cells were unable to induce T cells to proliferate (Fig. 2) . We noted that in cultures containing significant numbers of infected macrophages, e.g., at T cell/APC ratios of 10 (Fig. 3 A) . Significant killing was seen in the primary effector cell populations even at E/T ratios of 10:1 (Fig. 3 B) or less (data not shown). In contrast, macrophages were far less stimulatory, in the order of 100-fold or less, possibly due to the significant macrophage death observed after infection with virus. Since B cells are poor stimulators of the proliferative response to influenza and do not get infected with the virus (see above), it is unlikely that contaminating B cells in our dendritic cell population account for the CTL that are generated. OKM1, an mAb directed towards the CD1 lb antigen, known to remove NK cell precursors (8) , was used to deplete these cells from the starting T cell population. Thus, the effector cell population used in these assays is composed of T cells. Experiments to be described below showed the killers to be CD8+CD4-. Most donors, > 90%, could be stimulated to form CTLs with virus-infected dendritic cells, indicating that the majority of our donor pool has been exposed to influenza. Because CTL activity was measured on influenza A/PR8-infected targets, a strain first identified in 1934, and the prevalent strains are A/Texas/36/91 and A/Beijing/32/92, the CTLs generated appear to be cross-reactive, confirming other studies of human influenza-specific CTLs (18) .
Knowing that B cells do not contribute to CTL development, we next determined whether a partially purified preparation of dendritic cells (i.e., omitting the metrizamide column for enrichment) was adequate for generating CTL responses to influenza. ER-, FcR-preparations are depleted of most T cells and monocytes and consist of 5% dendritic cells, the remaining cells being primarily B cells. At T/APC ratios of 3:1 or 10:1, significant CTL responses were apparent (Fig. 4) . This corresponds to a T/dendritic cell ratio of 60:1 to 180:1. ER-, FcR-cells were used as stimulators for all subsequent experiments, in T/APC ratios varying from 3:1 to 5:1. These partially enriched populations (a) suffice to provide the cultures with dendritic cells in the 0.5-1.5% range, (b) lack inhibitory monocytes, and (c) are straightforward to prepare.
To ascertain when lytic activity was optimal, we measured A.. (Fig. 6) . To ascertain whether dendritic cell-induced CD8+, influenza-specific CTLs were class I restricted, we evaluated responses generated in two individuals who differed at class I loci but shared class II specificities (DRw52, DQw1). Donor A demonstrated significant lytic activity against syngeneic infected macrophage targets (Fig. 7) but lesser activity against class I mismatched targets (donor B macrophage targets). Likewise, donor B effector cells lysed syngeneic but not allogeneic (donor A) targets. The small degree of cross-reactivity seen in the case of A effectors versus B targets may be due to unspecified but shared class I antigens or, possibly, the development of CD4+-mediated CTL activity, which has been described in cloned human populations (31, 32) . However, the latter is less likely given that no CD4+ CTLs are generated in our system (see below).
Purified (33) .
Four features distinguish our system for generating CTLs from the bulk culture systems that have been used previously. First, only a few dendritic cells (0.5-1% suffice) are able to generate highly potent CTL, as demonstrated by the fact that killing is evident at EIT ratios of 1.5:1 (Fig. 5) . Such efficacy has not been described in CTLs generated from cultures of bulk PBMCs (13, 14, 18, 21) . Second, depletion of monocytes is necessary to remove potential inhibitory and toxic effects on the effector cells. In attempts to generate CTLs from unseparated PBMCs, we often observed significant cell death that prohibited killer cell development. This was likely secondary to cytopathic effects of viral infection in monocytes (Fig. 1) , as previously described (34, 35) . PBMCs contain about 1% dendritic cells (36) , and an Ia+ cell is known to be required for the generation of influenza virus-specific CTL in bulk PBMC culture systems (18) . We suggest that these small numbers of dendritic cells are sufficient to permit CTL development in circumstances where few monocytes are present or become infected. Third, although monocytes do not induce CTLs effectively, they serve as efficient targets in short-term chromium-release assays (5 h). During this time interval, a majority of monocytes express viral proteins as demonstrated by immunohistochemistry (data not shown). In contrast, standard target cells, e.g., B cell lines or PHA-treated lymphocytes, have a low level of infection (10-30%) and are less efficient in our hands as targets. Fourth, effector cell populations are routinely depleted of NK cells. These cells, which are activated by dendritic cells in vitro to lyse tumor cell targets (8) , may play a role in viral clearance. They are not ordinarily depleted in bulk culture systems and, therefore, could potentially mask specific CTL measurement.
APC requirements for the generation of influenza virusspecific CTLs. T cell-mediated immunity develops in two stages. In the afferent phase, dendritic cells bearing antigen initiate T-dependent responses from resting lymphocytes. Once activated, the sensitized T lymphoblasts can interact with other APCs in the efferent phase, to induce a number of effector functions, e.g., B cell antibody synthesis (37), macrophage activation, and IL-1 production (38) . As demonstrated here with influenza virus, dendritic cells serve in a similar capacity to first induce the generation of CD8+ CTLs, which then acquire the ability to kill infected macrophage targets. These pathways for CTL generation are potentially important for the prevention of cell-cell spread of virus. Several features may account for the observed differences between dendritic cells and monocytes in the induction of influenza-specific CTLs. One appears to be the manner in which influenza virus infection is handled by these two types of APCs. Greater than 90% of dendritic cells expressed HA, NP, (Fig. 1) and NS-1 (not shown) within 16 h and remained fully viable for > 24 h after infection. In sharp contrast, freshly isolated monocytes or week-old cultured macrophages were infected to CD4-independent Human Antiviral Cytolytic T Lymphocytes . Purified CD4+ and CD8+ T cells proliferate to influenza virus-infected dendritic cells. CD4+ and CD8+ T cells were purified from a bulk T cell population to > 98% by staining with specific mAbs, followed by sorting on a FACStar Plus, as described in Methods. Bulk T cells, sorted CD4+, CD8+, and a combination of both sorted populations (CD4/CD8 cell ratio of 2:1 ) were tested in a standard proliferation assay for responsiveness to influenza virus-infected ER-, FcR-cells. The T/APC ratio was 5: [40] , Leishmania [41] , and staphylococcal enterotoxins [42] ) efficiently to T cells. Dendritic cells are also distinguished from APCs like monocytes and B cells in the efficiency with which they deliver signals to the TCR-CD3 complex on T cells. For example, occupancy of only 0.1% of dendritic cell surface class II molecules with superantigen is sufficient to induce T cell proliferation (23) . This is due in part to the fact that dendritic cells express and upregulate many accessory molecules that are critical during the initiation of T cell immune responses (e.g., MLR [43] and superantigens [23] ). They include B7/BB1 (CD80), ICAM-1 (CD54), and LFA-3 (CD58), ligands for CD28, CD1 la, and CD2, respectively. Although we have yet to study the role of these accessory molecules on dendritic cells in CTL induction, there is evidence that interaction of CD28 with its ligand is a critical element in the activation of cytotoxic CD8+ T cells (44) . For example, murine class I restricted CTLs to alloantigens can be generated in the absence of help from CD4+ T cells, provided a CD28-B7 interaction occurs in the induction phase (44) . Furthermore, B7-transfected tumor cells can induce protective (CD8+ T cell-mediated) antitumor responses in vivo when CD4+ T cells are absent (45, 46) . If dendritic cells are key accessories in CTL induction, one would predict that these APCs should be effective in the generation of CTL responses to other antigens (e.g., melanoma antigens, alloantigens) where B7 is known to amplify the T cell response (43, 45, 46) . The CD28-B7/BB 1 interaction provides a critical costimulatory mechanism for IL-2 gene expression (47) (48) (49) Influenza-specific CD4+ CTL have been described in both human and mouse systems (16, 31, 32) . In contrast to CD8+ CTLs, CD4+ class H-restricted CTLs lysed target cells treated with noninfectious influenza virus or purified HA preparations and class II presentation was sensitive to lysosomotropic agents (16) . These differences provided critical early evidence that MHC class I-and class H-restricted CTL, depended upon divergent pathways for presentation of antigen. The role of CD4+ CTL in viral clearance and recovery from infection, however, remains to be determined. ,6-2-Microglobulin deficient (-/-) mice have few CD8+ T cells but can clear vaccinia virus and nonlethal HKX31 influenza A virus and resist a low inoculation dose of PR8 (56) , but recovery from lethal doses of the virulent strain seems to require the presence of CD8+ T cells (57) . In contrast, /8-2-microglobulin deficient (-/-) mice infected with LCMV intracranially develop CD4+ CTL that mediate disease, similar to their CD8+ counterparts in infected normal strains (58) .
Potential uses of CD8+ CTLs in influenza prophylaxis and therapy. Influenza A virus infection remains a major cause of mortality and morbidity, primarily because the control of the respiratory illness has not been achieved through vaccination. Current vaccines are designed to boost antibody responses to viral antigens (HA and NA) that undergo antigenic drift and shift (10 Targeting antigen to dendritic cells has several advantages: one can maximiz the efficiency of T cell activation (9) and avoid anergy induction (68) or the use of adjuvants (69) . For example, dendritic cells pulsed with antigen in vitro and delivered in vivo to mice have been highly effective for generating CD4+ immune responses to protein antigens and microbes (69, 70) . Mouse dendritic cells pulsed with class I-restricted peptides of NP (26) , HIV peptides (71), or given antigen via pH-sensitive liposomes (66) into the cytoplasm can induce CTL responses.
A pivotal role for dendritic cells in human disease prophylaxis and therapy is suggested by their ability to directly induce strong CD8+ CTL responses, as shown here for influenza virus. It may be possible to pulse dendritic cells directly with NP peptides or with attenuated virus, for instance, and use these APCs in vivo to elicit CTL responses. By adapting the systems developed in this study, dendritic cells could also be used for generating large numbers of CD8+ CTL, for adoptive transfer to immunosuppressed individuals who are unable to mount normal immune responses. Immunotherapy with CD8+ CTL has been shown to amplify the immune response. Bone marrow transplant recipients given CMV-specific CTL by adoptive transfer do not develop disease or viremia (4) . These novel approaches for immunoprophylaxis and therapy should be applicable to several situations where CD8+ CTLs are believed to play a therapeutic role, e.g., HIV infection (1-3), malaria (5) , and malignancies such as melanoma (6, 7).
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